Welcome to our dedicated page for Pharvaris N.V. news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris N.V. stock.
Pharvaris NV (PHVS) is a clinical-stage biopharmaceutical company pioneering oral therapies for hereditary angioedema (HAE) through bradykinin B2 receptor antagonism. This page provides investors and healthcare stakeholders with timely updates on clinical developments, regulatory milestones, and corporate news.
Access consolidated reports on deucrictibant's Phase 3 trials (RAPIDe-3, CHAPTER-3), partnership announcements, and financial disclosures. Our news collection features verified press releases and objective analyses of treatment advancements in rare disease therapeutics.
Key content includes updates on HAE treatment efficacy data, manufacturing partnerships, intellectual property developments, and conference presentations. Bookmark this page for direct access to PHVS's latest progress in transforming patient care through innovative oral medication alternatives.
Pharvaris, a late-stage biopharmaceutical company, will present clinical and nonclinical data at three upcoming congresses focusing on their oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE) attacks. The abstracts will cover topics like pharmacological profiles, relief of attack symptoms, efficacy, and safety of their treatments. The company aims to showcase their developments in the field and highlight the positive outcomes of their trials.
Pharvaris, a late-stage biopharmaceutical company with the stock symbol PHVS, reported strong financials with €368 million in cash, executing pivotal Phase 3 studies for HAE treatment, and preparing for commercial launch. The company's loss for Q1 2024 was €28.0 million, with R&D expenses at €18.5 million and G&A expenses at €9.8 million.
FAQ
What is the current stock price of Pharvaris N.V. (PHVS)?
What is the market cap of Pharvaris N.V. (PHVS)?
